The Role of Treatment Sequencing with Immune-Checkpoint Inhibitors and BRAF/MEK Inhibitors for Response and Survival of Patients with BRAFV600-Mutant Metastatic Melanoma—A Retrospective, Real-World Cohort Study

The Role of Treatment Sequencing with Immune-Checkpoint Inhibitors and BRAF/MEK Inhibitors for Response and Survival of Patients with BRAFV600-Mutant Metastatic Melanoma—A Retrospective, Real-World Cohort Study

The advent of immune-checkpoint inhibitors (CPI) and BRAF/MEK-directed targeted therapy (TT) has improved the treatment landscape of patients with BRAFV600-mutant metastatic melanoma. While TT allows for rapid disease control, the development of secondary TT resistance limits the duration of respons...

Full description

Bibliographic Details
Main Authors: Maximilian Haist, Henner Stege, Ronja Ebner, Maria Isabel Fleischer, Carmen Loquai, Stephan Grabbe
Format: Article
Language:English
Published: MDPI AG 2022-04-01
Series:Cancers
Subjects:
metastatic melanoma
sequential treatment
immune-checkpoint inhibitors
BRAF/MEK-inhibitors
targeted therapy
BRAF-mutation
Online Access:https://www.mdpi.com/2072-6694/14/9/2082

Internet

https://www.mdpi.com/2072-6694/14/9/2082

Similar Items